Table 4.
Molecular targeted therapies with demonstrated preclinical activity as radiosensitizers
| Epidermal Growth Factor Receptor inhibitors |
| Cetuximab |
| Gefitinib |
| Trastuzumab |
| CI-1033 (pan-ErbB tyrosine kinase inhibitor) |
| Farnesyl Transferase Inhibitors |
| FTI-277 |
| L744832 |
| BIM-46068 |
| Ras-Mediated Downstream Pathways inhibitors |
| AS-ON Raf |
| PI3K inhibitor: LY294002 |
| PI3K inhibitor: wortamannin |
| AS-ON p21 |
| MEK inhibitor |
| Agents that target apoptosis, cell cycle, NF-Kappa-B |
| Flavopiridol |
| PS-341 |
| UCN-01 |
| COX-2 Inhibitors |
| SC-236 |
| NC-398 |
| Rofecoxib |
| Antiangiogenic Agents |
| mAb-VEGF |
| SU5416 |
| SU5416 |
| SU6668 |
| mAb-VEGF-2 |
| Angiostatin |
| Endostatin |
| Histone deacetylase inhibitors |
| Valproic acid |
| MS275 |
| SAHA |